Brian Leedman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The majority of shareholders of a small digital health company in Brisbane have approved the $180 million (US$121 ...

Neurotech International (ASX:NTI) reported "breakthrough results" relating to the safety, tolerability, and efficacy of NTI164 and on key behavioural parameters that impact autism spectrum disorder (ASD) patients in its latest clinical study.

Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour

Article content An Australian-based company with an exclusive licence to a variety of rare cannabis cultivars is putting its plants to the test. Neurotech International (NTI) has begun a study to assess the safety and tolerability of its products to treat symptoms associated with autism in children. We apologize, but this video has failed to load. Try refreshing your browser, or Australian company studying impact of rare cannabinoids on autism Back to video In a release, the company reported it is currently working on a Phase I/II open label clinical study in 20 children aged five to 17 who...

Healthy Height® Kid Growth Solution Focuses on China USA - English News provided by Share this article Share this article TEL-AVIV, Israel, March 9, 2021 /PRNewswire/ -- Nutritional Growth Solutions, Ltd. (NGS), a public company trading in the Australian Stock Exchange (ASX: NGS), is expanding international activities for its Healthy Height® protein shake in China. Healthy Height has been clinically shown to improve children's height. This step forward is followed by a substantial growth in sales — 58% — in 2020. Healthy Height® Kid Growth Solution Focuses on China This result was driv...